Anthem Biosciences Share Price in Focus as IPO Sees Massive QIB Interest with 63.86x Subscription

Market Performance

The market is abuzz with interest in Anthem Biosciences' share price following the overwhelming response to its IPO. The company's ₹3,395 Crore public issue has become one of the most talked-about in 2025 due to strong institutional backing.

Shares of the company were seen trading with a premium in the grey market, signaling heightened investor interest ahead of the listing.

Main News: Anthem Biosciences IPO Oversubscribed 63.86 Times

The Anthem Biosciences IPO, which opened on July 14, 2025, saw a subscription of 63.86 times by the end of the bidding period. The offering received bids for 281.45 Crore shares, against just 4.40 Crore shares on offer.

Subscription Breakdown:

• Qualified Institutional Buyers (QIBs): 182.65 times
• Non-Institutional Investors (NIIs): 44.36 times
• Retail Investors: 5.64 times
• Employees: 6.60 times

The IPO was fully subscribed by the second day of bidding, signaling strong investor confidence.

In a notable highlight, Anthem Biosciences secured ₹1,016 Crore from anchor investors before the IPO.

In the grey market, the shares are commanding a premium of ₹144, hinting at a 25% listing gain over the issue price. However, this premium is unofficial and subject to rapid changes.

Company Details

Founded in 2006, Anthem Biosciences is a Contract Research, Development, and Manufacturing Organization (CRDMO). The company offers end-to-end services to global pharmaceutical and biotech clients—from early-stage research to commercial manufacturing.

Its integrated model helps streamline processes and reduce regulatory challenges for clients.

Key Details:

• Issue Price Band: ₹540 to ₹570
• IPO Size: ₹3,395 Crore
• Valuation at Upper Band: ₹31,800+ Crore
• IPO Type: Entirely Offer-for-Sale (OFS)
• No proceeds to the company; funds to selling shareholders

Book-Running Lead Manager: JM Financial

Registrar to the IPO: KFin Technologies

Financial Structure of the IPO

Though financial performance wasn't detailed in the IPO release, here's a quick snapshot of the IPO-related numbers:

• Total Issue Size: ₹3,395 Crore
• Anchor Investment: ₹1,016 Crore
• Price Band: ₹540 – ₹570
• Estimated Valuation: ₹31,800 crore+
• Implied Listing Gain: Approx. 25%

Important Dates

• IPO Opened: July 14, 2025
• IPO Closed: July 16, 2025
• Allotment Finalization: July 17, 2025
• Listing Date: Tentatively July 21, 2025
• Exchanges: BSE and NSE

Summary

The Anthem Biosciences share price is gaining significant traction as the IPO wraps up with a stellar 63.86x subscription rate. With strong support from QIBs (182.65x) and a premium seen in the grey market, investor sentiment appears bullish.

As the listing date nears, market watchers are closely monitoring the Anthem Biosciences share price trajectory. The company's strong positioning as a global CRDMO and the scale of its IPO have made it one of the standout listings of 2025.